Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBM588 + Pembrolizumab in Adjuvant High-Risk Resected RCC
NCT07037004Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Jul 2026
- Primary completion
- Oct 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of clostridium butyricum in renal cell carcinoma (RCC), sponsored by City of Hope. Started Jul 2026; status: recruiting.
02
Drugs
clostridium butyricum
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07037004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037004.